Physician profile
Manoj Mohan
NPI 1821295213
$9,999.80
in general payments reported to CMS, 2019-2025
33 companies · $1,763 in 2025
The $1,763 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,802 · 2020: $1,151 · 2021: $1,338 · 2022: $1,361 · 2023: $1,246 · 2024: $1,339 · 2025: $1,763.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,206 · Education: $143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,205.52 |
| Education | $142.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,520.23 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Glaxosmithkline, LLC. | $1,510.24 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genzyme Corporation | $957.75 | 2019-2025 | |
| Genentech USA, INC. | $532.00 | 2019-2025 | Xolair |
| Optinose US, INC. | $513.58 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $452.63 | 2024-2025 | Dupixent |
| Pfizer INC. | $334.54 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $313.35 | 2019-2025 | |
| Csl Behring | $285.70 | 2019-2025 | Haegarda, Andembry |
| Alk-Abello, INC | $264.30 | 2019-2025 | Standardized Mite D. Farinae, Timothy, Standardized, Pre-Pen |
| Teva Pharmaceuticals USA, INC. | $232.34 | 2019-2023 | Airduo Digihaler |
| Pharming Healthcare, INC. | $221.66 | 2019-2024 | Ruconest |
| Grifols USA, LLC | $217.73 | 2019-2024 | Prolastin-C Liquid |
| Kaleo, INC. | $194.37 | 2019-2024 | Auvi-Q |
| Boehringer Ingelheim Pharmaceuticals, INC. | $181.81 | 2020-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $173.58 | 2020-2025 | Eohilia, Hyqvia, Glassia |
| Ars Pharmaceuticals Operations, INC. | $161.31 | 2025 | Neffy |
| Abbvie INC. | $157.67 | 2020-2023 | |
| Amgen INC. | $133.85 | 2022-2025 | Tezspire |
| Organon LLC | $111.74 | 2025 | Vtama |
| Shire North American Group INC | $89.92 | 2019 | |
| Biocryst US Sales Co., LLC | $84.08 | 2021-2025 | Orladeyo |
| Covis Pharma Gmbh | $72.38 | 2021-2022 | |
| Phadia US INC. | $69.17 | 2020-2023 | Immunocap |
| Aimmune Therapeutics, INC. | $37.84 | 2021-2022 | |
| Hikma Pharmaceuticals USA | $31.82 | 2024-2025 | Ryaltris |
| Lilly USA, LLC | $30.91 | 2025 | Ebglyss, Taltz |
| Octapharma USA, INC. | $30.07 | 2019-2020 | |
| Biocryst Pharmaceuticals, INC. | $21.06 | 2020 | |
| Circassia INC. | $17.58 | 2019 | |
| Merck Sharp & Dohme LLC | $16.77 | 2023 | |
| Phathom Pharmaceuticals, INC. | $16.15 | 2024 | Voquezna |
| Leo Pharma INC. | $11.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manoj Mohan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.